Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 3/20 | 0.37 |
| ▸ | QPCT | Q16769 | 1/20 | 0.36 |
| ▸ | IDH1 | O75874 | 1/20 | 0.36 |
| ▸ | MAT2A | P31153 | 1/20 | 0.36 |
| ▸ | ELOVL1 | Q9BW60 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.34 |
| ▸ | PTH1R | Q03431 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | LOX | P28300 | 1/20 | 0.33 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.32 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL721033 | 0.81 | CHRNB2 (0.44) | IDH1ALDH1A1MAPK1 | |
| SCHEMBL20340466 | 0.80 | CYP17A1 (0.38) | CYP17A1IDH1MAT2AELOVL1ALDH1A1 | |
| SCHEMBL190640 | 0.75 | ALDH1A1 (0.55) | ALDH1A1MAPK1POLB | |
| SCHEMBL201840 | 0.73 | POLB (0.51) | ALDH1A1MAPK1POLBSLC6A9 | |
| SCHEMBL18961831 | 0.70 | LMNA (0.46) | SLC6A9 | |
| SCHEMBL719564 | 0.69 | CYP11B1 (0.45) | CHRNA7SLC6A9 | |
| SCHEMBL2544529 | 0.68 | MMP13 (0.46) | QPCTSLC6A9 | |
| SCHEMBL17077228 | 0.67 | MAPT (0.45) | ALDH1A1SLC6A9 | |
| SCHEMBL421867 | 0.67 | AKR1B1 (0.37) | QPCTALDH1A1MAPK1POLBSLC6A9 | |
| SCHEMBL242118 | 0.67 | SLC6A3 (0.40) | QPCT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10011601-B2 | Substituted spirocyclic inhibitors of autotaxin | X-RX, INC. (US) | 2018-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10011601-B2 | Substituted spirocyclic inhibitors of autotaxin | ENPP2, SLC10A1, CXCR3 | CYP17A1 230/4885QPCT 550/4885IDH1 2459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.